{"annotatable":{"parts":["s1v1","s2v1","s3v1","s4v1","s5v1","s6v1","s7v1","s8v1","s9v1","s10v1","s11v1","s12v1","s13v1","s14v1","s15v1","s16v1","s17v1"]},"anncomplete":true,"sources":[],"metas":{"m_82":{"value":"High-risk","confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1}},"m_83":{"value":"High-risk","confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1}},"m_84":{"value":"High-risk","confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1}},"m_85":{"value":"Low-risk","confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1}},"m_86":{"value":"High-risk","confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1}},"m_35":{"value":"High-risk","confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1}}},"entities":[{"classId":"e_107","part":"s1v1","offsets":[{"start":81,"text":"A PHASE III INTERNATIONAL RANDOMIZED CLINICAL TRIAL"}],"coordinates":[{"x":"380.12","y":"152.81"},{"x":"417.42","y":"181.14"}],"confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_109","part":"s1v1","offsets":[{"start":83,"text":"PHASE III INTERNATIONAL RANDOMIZED CLINICAL TRIAL"}],"coordinates":[{"x":"394.12","y":"152.81"},{"x":"417.42","y":"181.14"}],"confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_148","part":"s2v1","offsets":[{"start":1008,"text":"In an intention-to-treat analysis, the cumulative incidence of abnormal conversion was 9% (95% CI 0 to 35%) in the hydroxyurea arm and 47% (95% CI 6 to 81%) in observation arm at 15 months (p=0.16)."}],"coordinates":[{"x":"369.06","y":"224.82"},{"x":"411.38","y":"258.40"}],"confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_109","part":"s4v1","offsets":[{"start":41,"text":"SCATE was a Phase III, randomized, open label, partially masked, multi-center, international, prospective trial of hydroxyurea versus observation for children with SCA and centrally confirmed conditional TCD velocities"}],"coordinates":[{"x":"150.00","y":"82.82"},{"x":"339.42","y":"116.40"}],"confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_116","part":"s4v1","offsets":[{"start":41,"text":"SCATE was a Phase III, randomized, open label, partially masked, multi-center, international, prospective trial of hydroxyurea versus observation for children with SCA and centrally confirmed conditional TCD velocities."}],"coordinates":[{"x":"150.00","y":"82.82"},{"x":"341.92","y":"116.40"}],"confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_123","part":"s4v1","offsets":[{"start":76,"text":"open labe"}],"coordinates":[{"x":"302.19","y":"82.82"},{"x":"340.79","y":"88.40"}],"confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_128","part":"s4v1","offsets":[{"start":76,"text":"open label"}],"coordinates":[{"x":"302.19","y":"82.82"},{"x":"343.57","y":"88.40"}],"confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_190","part":"s4v1","offsets":[{"start":3073,"text":"The primary endpoint of the SCATE trial was the cumulative incidence of conversion to abnormal maximum TAMV velocities (in any of the 10 vessels measured)."}],"coordinates":[{"x":"150.00","y":"670.82"},{"x":"449.68","y":"690.40"}],"confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_109","part":"s5v1","offsets":[{"start":423,"text":"After randomization, participants received hydroxyurea treatment or observation, planned for a total of 30 months."}],"coordinates":[{"x":"150.00","y":"164.82"},{"x":"246.66","y":"184.40"}],"confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_148","part":"s5v1","offsets":[{"start":2504,"text":"The intention-to-treat principle was followed and all eligible, randomized participants were analyzed as randomized, in the primary analysis."}],"coordinates":[{"x":"193.89","y":"530.82"},{"x":"416.05","y":"550.40"}],"confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_165","part":"s6v1","offsets":[{"start":580,"text":"There were 4 children who dropped out during screening (due to not having a confirmatory TCD), while 12 were in screening at the time of study closure (Figure 1)"}],"coordinates":[{"x":"290.80","y":"200.82"},{"x":"221.65","y":"234.40"}],"confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_205","part":"s6v1","offsets":[{"start":1114,"text":"Premature Study TerminationThere was a regulatory delay of 18 months preventing importation of the study drug (hydroxyurea) at one site (HEMORIO). This delay was due to numerous administrative difficulties in obtaining formal approval by ANVISA (Agência Nacional de Vigilância Sanitária), the Brazilian government agency responsible for authorizing the entry of study drugs into the country. The SCATE study opened for enrollment in May 2012, and in August 2013 the study was suspended for new enrollments and randomization by the sponsor for slow patient accrual. The study was terminated in January 2014 due to slow accrual and the unlikelihood of meeting the study’s enrollment target and primary endpoint within the timeframe of funding. Due to the administrative delay in obtaining drug approval in Brazil, 2 of the 11 children randomly allocated to the treatment arm (hydroxyurea) did not initiate study drug as per protocol"}],"coordinates":[{"x":"90.00","y":"310.72"},{"x":"284.71","y":"474.40"}],"confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_216","part":"s6v1","offsets":[{"start":2765,"text":"The cumulative incidences of conversion from conditional to abnormal TAMV were 9% (95% CI 0 to 35%) and 47% (95% CI 6 to 81%) in the hydroxyurea and observation arms after 15 months, respectively (p = 0.16, Figure 2A). However, none of the participants"}],"coordinates":[{"x":"150.00","y":"654.82"},{"x":"495.02","y":"688.40"}],"confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1},"fields":{},"normalizations":{}},{"classId":"e_121","part":"s16v1","offsets":[{"start":100,"text":"Patient Characteristics at Baseline.Variable Randomization armHydroxyurea (N=11) Observation (N=11)Age (years) 6.2 (2.4) 6.6 (1.5)Gender (n,%)Males 4 (36) 4 (36)Females 7 (64) 7 (64)Ethnicity (n,%)Latino 2 (18) 3 (27)Non-Hispanic 9 (82) 8 (73)Race (n,%)Black 10 (91) 9 (82)White 1 (9) 2 (18)Genotype (n,%)HbSS 11 (100) 10 (91)HbSβ0thalassemia 0 (0) 1 (9)Hematologic indicesHb (g/dL) 7.5 (0.9) 7.7 (1.0)MCV (fL) 85.9 (5.0) 84.9 (10.8)ARC (×109/L) 316.8 (73.22) 381.3 (139.73)WBC (×109/L) 14.2 (4.0) 13.1 (4.9)ANC (×109/L) 5.9 (2.0) 4.9 (1.9)Platelets (×109/L) 474.2 (126.2) 388.1 (151.8)HbF (%) 9.9 (6.7) 9.4 (6.1)TCD ValuesOverall TAMV (cm/sec) 183.5 (8.5) 181.8 (6.4)Right side TAMV (cm/sec) 167.0 (15.1) 172.7 (14.9)Left side TAMV (cm/sec) 175.3 (3.9) 174.5 (15.6"}],"coordinates":[{"x":"78.00","y":"100.82"},{"x":"302.52","y":"539.16"}],"confidence":{"state":"pre-added","who":["user:roger-annotation"],"prob":1},"fields":{},"normalizations":{}}],"relations":[]}